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Abstract: Development of biomaterials for the diagnosis and treatment of neurotraumatic ailments has
been significantly advanced with our deepened knowledge of the pathophysiology of neurotrauma.
Canadian research in the fields of biomaterial-based contrast agents, non-invasive axonal tracing,
non-invasive scaffold imaging, scaffold patterning, 3D printed scaffolds, and drug delivery are
conquering barriers to patient diagnosis and treatment for traumatic injuries to the nervous system.
This review highlights some of the highly interdisciplinary Canadian research in biomaterials with a
focus on neurotrauma applications.
Keywords: biomaterials; nerve regeneration; neurotrauma; tissue engineering scaffold; imaging;
3D printing
1. Introduction
Neurotrauma can affect structures of the brain or spinal cord and often results in loss of motor,
sensory, and cognitive functions. While significant advances have taken place to help us understand
the pathophysiology of neurotrauma, our diagnosis and treatment strategies remain limited. Although
we have made significant strides in neuroprotection and neural regeneration, many of the therapeutic
agents cannot be simply administered systemically, i.e., oral and intravenous, as they can be either
readily inactivated, cannot cross the blood–brain/spinal cord barrier (BBB/BSCB) [1,2], are rapidly
degraded in the circulatory system [3], or cause significant systemic side effects when systemically
administered [4]. Outcomes of attempts to stimulate the central nervous system’s axonal regeneration
have been limited due to poor control of the extent and direction of the growth processes. Strategies
to stimulate regeneration involving cell implantations, including stem and progenitor cell therapies
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have also been met with challenges such as cell survival, integration and restoration of the damaged
neural circuitry [5]. As a result, biomaterials have been developed to overcome these issues in order to
improve the diagnosis and treatment of neurotrauma patients.
Biomaterials are used for medical applications and are intended to interact with biological systems [6].
The successful creation of biomaterials is highly interdisciplinary, involving collaborations between experts
with different backgrounds, including engineers, chemists, physicists, biologists, neuroscientists, and
clinicians. In this review, we will focus on the current advances made by Canadian biomaterial researchers
with respect to neurotrauma diagnosis and repair with potential clinical and preclinical applications.
2. Diagnostic Biomaterials
Traditional uses of biomaterials for diagnosis have been limited to polymeric biomaterial probes
for magnetic resonance imaging (MRI) and positron emission tomography (PET) modalities [7].
Emerging diagnostic biomaterials can both improve the accuracy of patient diagnosis and expedite the
development of neural regenerative treatments.
2.1. Contrast Agents
Aptamers are short, single stranded synthetic nucleic acids (DNA or RNA) selected from combinatorial
libraries for their ability to bind specifically to molecular targets [8]. Aptamers have excellent molecular
recognition abilities that make them uniquely suited for drug delivery, diagnostic, and therapeutic
applications [9,10]. Using systematic evolution of ligands by exponential enrichment (SELEX), DeRosa et al.
developed and studied different aptamers for a variety of molecular targets, including neurotransmitters,
cancer biomarkers, and viruses [11,12], and further developed aptamer-based MRI and computed
tomography (CT) contrast agents by conjugating the aptamers and the contrast agents (as seen in
Figure 1) for detection of intercranial thrombus in neurotraumatic patients [13,14]. Current research efforts
are focused on developing new aptamer-based contrast agents to image fibrin in attempts to localize
intercranial blood clots for early detection, as clinical treatment options for intercranial blood clots and
prevention of their complications are highly dependent on early detections [15].
Figure 1. High resolution transmission electron microscopy (HRTEM) images of small, monodispersed
Fe3O4 nanoparticles (NPs) as contrast agents in diphenyl ether observed under different magnifications.
Reprinted under a Creative Commons Attribution 4.0 International License from Reference [13] from
journal MethodsX.
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Development of a non-invasive imaging modality for scaffold monitoring can improve biomaterial
design to gain a better understanding of the implanted scaffold, such as in vivo degradation process
during preclinical development. Specifically, non-invasive imaging would eliminate the need for open
surgical exploration and histological examination, thereby reducing animal sacrifice and decreasing the
cost associated with animal studies [16]. For example, synchrotron-based imaging methods have been
used to visualize and characterize scaffolds once the scaffolds are implanted [17,18]. This interesting
approach to monitoring scaffolds implanted in animal models may eventually find applications in
human patients.
2.2. Non-Invasive Axonal Tracing
Anterograde and retrograde axonal tracing techniques are well established tracing techniques
in the field of neuroscience and allow for assessment of neuronal connections between neurons
and neural projections [19,20]. Axon tracing techniques are commonly used in neural regenerative
therapies. Traditional axon tracers, such as biotinylated dextran amine (BDA), Fluoro-Gold (FG) and
1,1′-dioctadecyl-3,3,3,3-tetramethyl-indocarbocyanine perchlorate (DiI) are used to enable detailed
microscopy observation of axons but are limited by their inability to provide non-invasive observations
of axon regeneration [21–24]. Using superparamagnetic iron oxide (SPIO), Du et al. have designed a
novel, tri-functional bio-nanomaterial that incorporates a superparamagnetic core for MRI contrast,
a fluorescent shell for optical detection, and a BDA-functionalized shell for potential axonal tracing,
as seen in Figure 2 [25]. The results show that the SPIOs are biocompatible and that they can be readily
taken up by live cells. The research also demonstrates that the SPIOs can generate sufficient MRI
signals for MR imaging. This interesting nanoparticle-based fluorescent anterograde tracer can serve
as a diagnostic tool that could potentially enable axonal tracing using MRI thus significantly reducing
the numbers of animals used in scientific studies.Processes 2019, 7, x FOR PEER REVIEW 4 of 13 
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(a) Schematic representation of the axon tracer design showing a superparamagnetic iron oxide 
(SPIO) core, a middle layer of Fluorescein isothiocyanate (FITC)-doped silica, and the external layer 
of biotinylated dextran amine (BDA). Fluorescent confocal micrographs of (b) undifferentiated and 
(c) differentiated N2a cells that have taken up SPIO@SiO2(FITC)-BDA nanoparticles. Reprinted with 
permission from Reference [25]. 
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clinically relevant to help patients who sustain neural injuries. For example, tissue engineering 
scaffolds made from biomaterials have combined both neuroscience and engineering approaches [26–
30]. To this end, scaffolds are designed to act as structural supports for axonal growth and/or as 
vehicles for cell transplantation and drug delivery of therapeutic agents to promote nerve 
regeneration. Unlike tissues from other organs that typically form fibrous scars after injuries, 
damaged CNS tissues undergo liquefactive necrosis and cavitation [31]. Therefore, biomaterials for 
CNS applications are required to anchor and protect cells in addition to supporting cell growth and 
functions. These materials commonly include naturally occurring biomaterials such as Matrigel and 
collagen, and synthetic biomaterials, such as poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene 
glycol) (PEG) [32–36]. Naturally occurring biomaterials have excellent biocompatibility due to their 
intrinsic properties being similar to the extracellular matrix (ECM) in the body [37]. Unfortunately, 
due to their biological origins, natural polymers are also vulnerable to degradation which may 
significantly compromise the mechanical stability over time. In comparison, synthetic biomaterials 
are relatively biologically inert and consequently lack cell-material interactions; however, these 
synthetic biomaterials have well-defined compositions [38], are generally mechanically strong, and 
can be readily tailored for neurotrauma applications. In addition, since both cell adhesion motifs and 
material architectures have been shown to be important in promoting nerve regenerations, 
researchers have attempted to modify synthetic materials to achieve better cell-material interactions. 
For example, poly(L-lactide) (PLLA) has been surface modified with laminin to improve neural cell 
adhesion and stem cell survival [39–41]. Specifically, He et al. synthesized PLLA nanofibers by 
electrospinning and modified the PLLA surface by adding multilayers of laminin-chitosan. The 
researchers showed that the resulting scaffold mimicked the structures and functionalities of ECM. 
In fact, PLLA-laminin-chitosan scaffold was shown to promote greater neurite outgrowth from dorsal 
root ganglion (DRG) neurons and neonatal mouse cerebellum C17.2 stem cells in comparison with 
the native PLLA scaffolds [41]. In addition, scaffold architectures, both microarchitecture — which 
encompasses topographical features of cells—and macroarchitecture—which encompasses spatial 
organization in a tissue level—have been demonstrated to provide frameworks for successful neural 
regeneration and tissue integration. For example, architectures of microfibers prepared from PLGA, 
poly(ɛ-caprolactone) (PCL), and poly(ether sulfone) (PES) have been investigated for their effects on 
Figure 2. Trifunctional nanomaterial SPIO@SiO2(FITC)-BDA and its application as an axonal tracer.
(a) Schematic representation of the axon tracer design showing a superparamagnetic iron oxide (SPIO)
core, a middle layer of Fluorescein isothiocyanate (FITC)-doped silica, and the external layer of
biotinylated dextran amine (BDA). Fluorescent confocal micrographs of (b) undifferentiated and (c)
differentiated N2a cells that have taken up SPIO@SiO2(FITC)-BDA nanoparticles. Reprinted with
permission from Reference [25].
3. Therapeutic Biomaterials
Recently, there has been extensive interest in the development of three-dimensional (3D) polymer
scaffolds for neural regeneration and repair after central nervous system (CNS) injuries. Although
basic neuroscience continues to be the predominant focus in the field of axon regeneration, research
focuses have also been placed on the development of bioengineered strategies that are clinically
relevant to help patients who sustain neural injuries. For example, tissue engineering scaffolds made
from biomaterials have combined both neuroscience and engineering approaches [26–30]. To this
end, scaffolds are designed to act as structural supports for axonal growth and/or as vehicles for
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cell transplantation and drug delivery of therapeutic agents to promote nerve regeneration. Unlike
tissues from other organs that typically form fibrous scars after injuries, damaged CNS tissues undergo
liquefactive necrosis and cavitation [31]. Therefore, biomaterials for CNS applications are required
to anchor and protect cells in addition to supporting cell growth and functions. These materials
commonly include naturally occurring biomaterials such as Matrigel and collagen, and synthetic
biomaterials, such as poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) [32–36].
Naturally occurring biomaterials have excellent biocompatibility due to their intrinsic properties being
similar to the extracellular matrix (ECM) in the body [37]. Unfortunately, due to their biological
origins, natural polymers are also vulnerable to degradation which may significantly compromise
the mechanical stability over time. In comparison, synthetic biomaterials are relatively biologically
inert and consequently lack cell-material interactions; however, these synthetic biomaterials have
well-defined compositions [38], are generally mechanically strong, and can be readily tailored for
neurotrauma applications. In addition, since both cell adhesion motifs and material architectures have
been shown to be important in promoting nerve regenerations, researchers have attempted to modify
synthetic materials to achieve better cell-material interactions. For example, poly(L-lactide) (PLLA)
has been surface modified with laminin to improve neural cell adhesion and stem cell survival [39–41].
Specifically, He et al. synthesized PLLA nanofibers by electrospinning and modified the PLLA
surface by adding multilayers of laminin-chitosan. The researchers showed that the resulting scaffold
mimicked the structures and functionalities of ECM. In fact, PLLA-laminin-chitosan scaffold was shown
to promote greater neurite outgrowth from dorsal root ganglion (DRG) neurons and neonatal mouse
cerebellum C17.2 stem cells in comparison with the native PLLA scaffolds [41]. In addition, scaffold
architectures, both microarchitecture — which encompasses topographical features of cells—and
macroarchitecture—which encompasses spatial organization in a tissue level—have been demonstrated
to provide frameworks for successful neural regeneration and tissue integration. For example,
architectures of microfibers prepared from PLGA, poly(ε-caprolactone) (PCL), and poly(ether sulfone)
(PES) have been investigated for their effects on neural stem cell proliferation and differentiation.
It was found that fiber diameters in the range of 500–800 nm promoted optimal cell proliferation and
neuronal differentiation [38,42,43].
3.1. Cell Patterning Using Biomaterials
Novel patterning techniques have been used to direct neuronal growth directionalities and promote
nerve regenerations. Hyaluronic acid (HA) is a transparent biomaterial that is naturally found in the
extracellular matrix and present in connective tissues in the body. Since the material is slightly negatively
charged, it does not allow cell adhesion [14].However, when modified with an arginine-glycine-aspartic
acid-serine (RGDS) peptide sequence, a cell permissive fibronectin recognition site, the originally cell
non-permissive HA can be rendered cell permissive after the RGDS modification. To this end, RGDS
peptide sequence has been covalently linked to 2-nitrobenzyl, a photolabile functional group that can
completely mask the cell adhesive property of the RGDS sequence when it is chemically attached to
the peptide, i.e., photocaged, and resume the cell adhesive property of the peptide upon exposure
to lights, i.e., photo uncaged, rendering the peptide cell permissive. As a result, these photocaged
peptides are initially bound to the HA matrix to form a cell non-permissive HA matrix, which is
subsequently patterned with cell permissive regions by selectively uncaging the HA surface by light
illumination. Using this method, Goubko et al. have successfully prepared alternating cell permissive
and non-permissive patterns on two-dimensional hydrogel surfaces and have discovered that by
caging RGDS at different amino acid residue locations, the photolysis and the stability of the caged
peptides are significantly different [44,45]. This new observation has significant impact on these caged
peptides and scaffold patterning used in various applications in neural regeneration.
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3.2. 3D Bioprinted Bioactive Biomaterials
Scaffolds with living cells and/or bioactive molecules can be fabricated using 3D bioprinting
techniques, where a scaffold is fabricated by laying down threads or fibers of bioink, i.e., the mixture
of hydrogel, living cells, and/or bioactive molecules, in a controllable layer-by-layer manner [46].
Specifically, Chen et al. have illustrated the feasibility of bioprinting scaffolds from alginate hydrogel or
a composite hydrogel mixture of alginate and hyaluronic acid, with both controlled microstructure and
controlled distribution of living Schwann cells for use in peripheral nerve repair applications [26,47–51].
In addition, the researchers also developed methods to address key issues involved in the 3D bioprinting
process, including printability, cell viability, and neurite outgrowth [26,47,48,52]. To mimic biological
features that are important in promoting axon regeneration, scaffolds are also micro-patterned with
laminin [53]. In this study, the researchers combine laminin and chitosan to promote axon guidance
in cultured adult dorsal root ganglion (DRG) neurons. Using a dispensing-based rapid prototyping
(DBRP) technique, the researchers create two-dimensional grid patterns by dispensing the two
compositions, i.e., chitosan or laminin-blended chitosan substrates, in orthogonal directions. Results
from this experiment demonstrates that DRG neurites on these patterns preferentially follow the
laminin-blended chitosan pathways, suggesting that patterned scaffold can enhance and direct axonal
growth in vitro. In addition, further study demonstrates that 3D printed scaffolds loaded with living
Schwann cells are effective in promoting axon growth in vitro and shows exciting potentials in nerve
regeneration in vivo [29].
Bioactive scaffolds, including 3D printed devices, multifunctional electrospun scaffolds, and drug
releasing microspheres have been used to promote differentiation of pluripotent stem cells into neural
tissues [54–62]. In particular, novel 3D printed fibrin formulations produced by the Willerth Lab have
been shown to promote mouse and human induced pluripotent stem cell differentiations to form neural
tissues that consist of different neuronal phenotypes [54,55,60,61]. As shown in Figure 3, the researchers
use genipin to crosslink fibrin matrix in order to increase the resulting fibrin scaffold stability while
decreasing the degradation rate of fibrin. The results show that genipin crosslinking alters the physical
characteristics of the fibrin scaffolds and influences the behaviour of the differentiating cells seeded
inside. Furthermore, this provides additional insight into how 3D fibrin scaffolds can be optimized
to promote neural differentiation from pluripotent stem cells, which has real potential in neuronal
tissue engineering to repair damaged nervous systems [56,58,59]. Three-dimensional cell culture and
bioprinting hydrogel technologies can also be used to simulate in vivo biochemical environments
to improve drug screening, understand complex mechanisms of disease, and create implantable
cell-hydrogel constructs for tissue repairs [63]. For example, Wylie et al. have developed a temporal
hydrogel patterning system to mimic the dynamic biochemical environment of the extracellular
matrix [64] and have developed 3D patterning using two-photon chemistry inside transparent 3D
agarose hydrogels [65,66]. In the future, it can be expected that these technologies can be used to
control cellular activities and design artificial tissues or organs for both in vitro drug screening and
in vivo implantations.
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Figure 3. Scanning electron microscopy images of three-dimensional printed fibrin scaffolds crosslinked
with different concentrations of genipin: (a) 0 µM, (b) 1 µM, (c) 2.5 µM, (d) 5 µM, and (e) 10 µM.
Reprinted under a Creative Commons Attribution 4.0 International License from Reference [61] from
the journal Scientific Reports.
3.3. 3D Biomaterials for Drug Delivery Systems
In addition to providing support for tissue structures, emerging neural therapeutic biomaterials
have been used to combine tissue engineering scaffolds with drug delivery. While drug related research
has long been focused on the discovery and synthesis of new and more potent drugs to treat diseases,
recently there has been a shift in research focus towards the delivery of different drug formulations
within the body [67]. The demand for drug delivering systems in the nervous system ranges from the
need for specific, local, and sustained release of drugs to targeted regenerative processes, and this is
particularly true for the CNS. While many therapies have shown promises to enhance regeneration
in preclinical studies, translating these therapies to human patients remains a significant challenge.
The BBB/BSCB is a protective barrier of the CNS, protecting the brain and the spinal cord against harmful
agents; as a result, this barrier also significantly reduces efficacies of systemic drug delivery methods, i.e.,
oral and intravenous [68]. Given the special structure of the BBB/BSCB, new therapeutic drug designs
or elaborations of efficient delivery methods are required for CNS drug deliveries [69]. For example,
in the case of spinal cord injury, serial injections or continuous osmotic mini-pump infusions have
been used to deliver high concentrations of therapeutic drugs to the spinal cord intrathecal space via
infusion pumps [70]. Intrathecal delivery is commonly used in patients with cancer-related pains
to allow for specific and focused dosing of opioids for pain control while circumventing systematic
side effects [71,72]. Direct intrathecal drug delivery has also been shown to be a promising delivery
method in spinal cord injury (SCI) animal models [73–75]. However, these methods present several
key limitations, such as uneven distribution of the released drugs with serial injections, increased
risk of infection, and obstructed catheters [68]. To solve these issues, injectable hydrogels have been
used to facilitate intrathecal drug delivery. For example, Hamann et al. have studied an injectable
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hydrogel formulation composed of a high concentration of collagen, which can be quickly solidified
after intrathecal injection into the subarachnoid space [76]. This collagen based hydrogel has been
shown to persist in the injection site for at least 8 weeks without eliciting an inflammatory reaction [76].
Another interesting example of localized drug delivery for CNS regeneration is an injectable guanosine
5′-diphosphate (GDP)-crosslinked chitosan sponge [77,78]. This injectable chitosan sponge has been
shown to enhance remyelination post SCI due to its unique chemical composition and its localized
delivery of neurotrophic factors that promote oligodendrocyte progenitor differentiation. Similarly,
the same chitosan sponges are also shown to be excellent candidates to encapsulate and deliver
growth factors such as bone morphogenetic proteins (BMPs), with over 85% encapsulation efficiency
and can differentiate calvarial pre-osteoblasts into functional mature osteoblasts [79]. A schematic
illustration of preparations of the GDP cross-linked chitosan sponge is shown in Figure 4. Interestingly,
Wylie et al. have recently reported a hydrogel-based delivery system with the ability to tune the release
of bioactive proteins for up to 100 days using a competitive affinity mechanism [80]. The competitive
affinity release is a result of the disruption of protein–hydrogel interactions by a competitive binder.
More specifically, streptavidin (SA)–antibody conjugates are incorporated in an agarose–desthiobiotin
hydrogel through desthiobiotin–SA complexation, which is designed to be disrupted by dissolution
of sparingly soluble biotin derivative pellets to competitively bind SA. As a result of the competitive
binding pairs, the presence of biotin derivatives in the releasing solution continually compete for
binding sites made available by the streptavidin(SA)–antibody conjugate inside of the hydrogel, thereby
achieving release of the attached antibody from the hydrogel. While the model drug used in this study
is an antibody, it can be expected that other protein based drugs or molecules, such as growth factors
can also be released in a similar fashion to achieve drug release for an extended period of time. This is
significant because in comparison with the invasive nature of traditional methods to deliver drugs
to the CNS, this long-term drug delivery system is expected to minimize injection frequencies for
potential therapies.Processes 2019, 7, x FOR PEER REVIEW 8 of 13 
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Figure 4. Electrostatic interaction between anionic guanosine 5′-diphosphate (GDP) and cationic
chitosan leads to the for ation of highly porous scaffold. The encapsulation of adult adipose stem cells
(ASCs) and pyrophosphatase (PPtase) can break down GDP and release phosphate ions to promote the
bio ineralization in a critical size bone defect (CSBD). The image shows the chitosan sponge in CBSD
to illustrate the localization of the sponge. There is no need for open surgery in clinical use since the
sponge can be directly injected into the CSBD.
It is well established that the presence of myelin-associated growth inhibitory proteins such as
Nogo-A is one of the main reasons why the adult CNS cannot successfully regenerate after SCI. These
inhibitory proteins, i.e., Nogo-A, bind and activate the Nogo-66 receptor that is known to facilitate
axonal growth inhibition, leading to profound inhibition of growth cone motilities. To overcome this
inhibitory environment, alginate microspheres have been used as drug delivery systems to deliver
Nogo receptor-blocking peptides to antagonize the inhibitory effect of Nogo-A on axon growth [81,82].
These microspheres, used either alone or incorporated into tissue engineering scaffolds, can be used to
overcome—at least partially—the inhibitory environments in the CNS to improve nerve regeneration.
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Axonal guidance channels that act as physical guidance and create a permissive environment for
regenerating neurons have been used as part of entubulation strategies in the SCI [83] and peripheral
nervous system (PNS) [84] nerve regeneration repair applications. For example, Tsai et al. have
prepared hollow fiber guidance channels that have been shown to promote axonal regeneration in a
complete rat spinal cord transection model [85]. In addition, when these channels are further filled
with matrices such as collagen, fibrin, and methylcellulose supplemented with different growth factors,
total axon densities within these matrix-filled channels have been showed to increase significantly in
comparison with the unfilled channels, suggesting that matrix filled nerve guides in combination with
growth factors can improve axonal regeneration after the SCI [83].
4. Conclusions
Canadians researchers have been at the forefront at developing biomaterials-based strategies to
overcome the complex challenges associated with neurotrauma, particularly with respect to biomaterials
for diagnosis, imaging and therapeutic scaffolds for drug delivery and axon guidance. Although the
effects of traumatic brain and spinal cord injuries are devastating for patients and their families, it is
expected that the application of biomaterials in the field of neurotrauma will expedite the development
and implementation of promising therapies and ultimately enhance the successful translation of these
therapies to humans.
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